Clinical Significance of mdm2 and p53 Expression in Bladder Cancer

Publisher： Karger

E-ISSN： 1423-0232|56|3|239-247

ISSN： 0030-2414

Source： Oncology, Vol.56, Iss.3, 1999-04, pp. : 239-247

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Significance of Protein p53 Overexpression in the Clinical Course of High-Risk Superficial Bladder Cancer

By  

Urologia Internationalis, Vol. 70, Iss. 3, 2003-04 ,pp. : 172-177

Karger

Access to resources Recommend Favorite

Targeted nutlin-3a loaded nanoparticles inhibiting p53––MDM2 interaction: novel strategy for breast cancer therapy

By Das Manasi   Dilnawaz Fahima   Sahoo Sanjeeb K  

Nanomedicine, Vol. 6, Iss. 3, 2011-04 ,pp. : 489-507

Future Medicine

Access to resources Recommend Favorite

mdm2-p53 Interaction: Lack of Correlation with the Response to 5-Fluorouracil in Advanced Colorectal Cancer

By  

Oncology, Vol. 62, Iss. 3, 2002-06 ,pp. : 278-285

Karger

Access to resources Recommend Favorite

Expression and Clinical Significance of SOX9 in Renal Cell Carcinoma, Bladder Cancer and Penile Cancer

By  

Oncology Research and Treatment, Vol. 40, Iss. 1-2, 2017-01 ,pp. : 15-20

Karger

Access to resources Recommend Favorite

p53 Gene Mutations in Superficial Bladder Cancer

By  

Urologia Internationalis, Vol. 73, Iss. 3, 2004-11 ,pp. : 212-218

Karger

Access to resources Recommend Favorite